JPMorgan Chase & Co. Reaffirms “Neutral” Rating for Blueprint Medicines (NASDAQ:BPMC)
Blueprint Medicines (NASDAQ:BPMC – Get Free Report)‘s stock had its “neutral” rating restated by investment analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $129.00 target price on the biotechnology company’s stock, down from their prior target price of $130.00. JPMorgan Chase […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report)‘s stock had its “neutral” rating restated by investment analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $129.00 target price on the biotechnology company’s stock, down from their prior target price of $130.00. JPMorgan Chase […]
